Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Lancet Haematol
; 7(11): e798-e807, 2020 Nov.
Article
in En
| MEDLINE
| ID: mdl-32971036
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Hematopoietic Stem Cell Transplantation
/
Lymphoma, Mantle-Cell
/
Cytarabine
/
Antibodies, Monoclonal, Humanized
Type of study:
Etiology_studies
/
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Humans
/
Middle aged
Language:
En
Journal:
Lancet Haematol
Year:
2020
Document type:
Article